abrezekimab

Ligand id: 9806

Name: abrezekimab

Immunopharmacology Comments
UCB4144 is a novel dry-powder formulation for inhalation that contains a high-affinity neutralizing anti-human-IL-13 monoclonal antibody fragment developed for the treatment of severe uncontrolled Th2-driven asthma.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Phase 1 clinical candidate for asthma- see NCT02473939